

Marco Colleoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5144897/publications.pdf>

Version: 2024-02-01

370
papers

32,518
citations

5574

82
h-index

4645

170
g-index

376
all docs

376
docs citations

376
times ranked

23018
citing authors

#	ARTICLE	IF	CITATIONS
1	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. <i>Annals of Oncology</i> , 2013, 24, 2206-2223.	1.2	2,805
2	Tailoring therapies“improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015, 26, 1533-1546.	1.2	1,449
3	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 425-439.	10.7	1,344
4	Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. <i>Lancet</i> , The, 2015, 386, 1341-1352.	13.7	1,072
5	Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23“01): a phase 3 randomised controlled trial. <i>Lancet Oncology</i> , The, 2013, 14, 297-305.	10.7	998
6	De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. <i>Annals of Oncology</i> , 2017, 28, 1700-1712.	1.2	844
7	Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98. <i>Journal of Clinical Oncology</i> , 2007, 25, 486-492.	1.6	835
8	Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 1926-1936.	27.0	805
9	Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen. <i>Journal of Clinical Oncology</i> , 2010, 28, 509-518.	1.6	716
10	Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 307-316.	27.0	656
11	Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 904-915.	10.7	648
12	Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 107-118.	27.0	621
13	Adjuvant Ovarian Suppression in Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 436-446.	27.0	588
14	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 122-137.	27.0	448
15	Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents. <i>Cancer Cell</i> , 2008, 14, 263-273.	16.8	424
16	Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. <i>Annals of Oncology</i> , 2002, 13, 73-80.	1.2	421
17	Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. <i>Journal of Clinical Oncology</i> , 2016, 34, 927-935.	1.6	390
18	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021, 32, 1216-1235.	1.2	354

#	ARTICLE	IF	CITATIONS
19	Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. <i>Lancet Oncology, The</i> , 2018, 19, 1385-1393.	10.7	342
20	Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors. <i>Clinical Cancer Research</i> , 2004, 10, 6622-6628.	7.0	333
21	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b trial. <i>Lancet Oncology, The</i> , 2019, 20, 371-382.	10.7	327
22	International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?. <i>Journal of the National Cancer Institute</i> , 2010, 102, 456-463.	6.3	325
23	Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. <i>Annals of Oncology</i> , 2007, 18, 1927-1934.	1.2	324
24	Very young women (<35 years) with operable breast cancer: features of disease at presentation. <i>Annals of Oncology</i> , 2002, 13, 273-279.	1.2	301
25	Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4899-4905.	1.6	280
26	Depression and degree of acceptance of adjuvant cytotoxic drugs. <i>Lancet, The</i> , 2000, 356, 1326-1327.	13.7	274
27	Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1169-1178.	1.6	266
28	Adjuvant Chemotherapy Followed by Goserelin Versus Either Modality Alone for Premenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1833-1846.	6.3	261
29	Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. <i>Blood</i> , 2006, 108, 452-459.	1.4	242
30	Clinical Relevance of HER2 Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5693-5699.	1.6	235
31	Tamoxifen After Adjuvant Chemotherapy for Premenopausal Women With Lymph Node-Positive Breast Cancer: International Breast Cancer Study Group Trial 13-93. <i>Journal of Clinical Oncology</i> , 2006, 24, 1332-1341.	1.6	215
32	Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2008, 100, 207-212.	6.3	215
33	Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. <i>Annals of Oncology</i> , 2010, 21, 1974-1981.	1.2	202
34	Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). <i>Oncologist</i> , 2016, 21, 1165-1175.	3.7	183
35	Early Start of Adjuvant Chemotherapy May Improve Treatment Outcome for Premenopausal Breast Cancer Patients With Tumors not Expressing Estrogen Receptors. <i>Journal of Clinical Oncology</i> , 2000, 18, 584-584.	1.6	181
36	Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. <i>Journal of Clinical Oncology</i> , 2016, 34, 2452-2459.	1.6	178

#	ARTICLE	IF	CITATIONS
37	Breast carcinoma in elderly women. <i>Cancer</i> , 2004, 101, 1302-1310.	4.1	176
38	Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 317-328.	2.5	172
39	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. <i>Journal of Clinical Oncology</i> , 2021, 39, 1448-1457.	1.6	171
40	Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. <i>Annals of Oncology</i> , 2008, 19, 1090-1096.	1.2	168
41	Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. <i>Annals of Oncology</i> , 2006, 17, 232-238.	1.2	166
42	Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. <i>Annals of Oncology</i> , 2009, 20, 1489-1498.	1.2	163
43	Size of Breast Cancer Metastases in Axillary Lymph Nodes: Clinical Relevance of Minimal Lymph Node Involvement. <i>Journal of Clinical Oncology</i> , 2005, 23, 1379-1389.	1.6	153
44	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer" The Penelope-B Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1518-1530.	1.6	153
45	Breast phyllodes tumor: A review of literature and a single center retrospective series analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 427-436.	4.4	150
46	Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor"Positive, Human Epidermal Growth Factor Receptor 2"Negative Early Breast Cancer: TEXT and SOFT Trials. <i>Journal of Clinical Oncology</i> , 2016, 34, 2221-2231.	1.6	148
47	Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. <i>Lancet Oncology</i> , The, 2015, 16, 848-858.	10.7	145
48	Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2772-2779.	1.6	141
49	Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. <i>Breast Cancer Research</i> , 2014, 16, R65.	5.0	138
50	Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 1117-1124.	1.6	134
51	Letrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 1972-1979.	1.6	133
52	Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 249-256.	10.7	130
53	Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome. <i>Clinical Breast Cancer</i> , 2013, 13, 31-39.	2.4	128
54	Invasive lobular breast cancer: subtypes and outcome. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 713-723.	2.5	126

#	ARTICLE	IF	CITATIONS
55	Cardiovascular Adverse Events During Adjuvant Endocrine Therapy for Early Breast Cancer Using Letrozole or Tamoxifen: Safety Analysis of BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 5715-5722.	1.6	125
56	Sentinel Node Biopsy Is Not a Standard Procedure in Ductal Carcinoma In Situ of the Breast. <i>Annals of Surgery</i> , 2008, 247, 315-319.	4.2	124
57	Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. <i>Annals of Oncology</i> , 2014, 25, 1979-1987.	1.2	122
58	Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. <i>European Journal of Surgical Oncology</i> , 2016, 42, 361-368.	1.0	122
59	Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer: Results From Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2966-2973.	1.6	121
60	Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. <i>Lancet</i> , The, 2005, 366, 1108-1110.	13.7	118
61	Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. <i>Journal of Clinical Oncology</i> , 2018, 36, 1941-1948.	1.6	116
62	Therapeutic effect of β -blockers in triple-negative breast cancer postmenopausal women. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 567-575.	2.5	113
63	Clinical overview of metronomic chemotherapy in breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 631-644.	27.6	109
64	Robotic nipple-sparing mastectomy for the treatment of breast cancer: Feasibility and safety study. <i>Breast</i> , 2017, 31, 51-56.	2.2	109
65	Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3967-3975.	1.6	108
66	Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. <i>BMC Cancer</i> , 2006, 6, 225.	2.6	103
67	Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab. <i>Clinical Cancer Research</i> , 2009, 15, 7652-7657.	7.0	102
68	Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 3113-3122.	1.6	101
69	Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 323-331.	2.5	100
70	Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1601-1610.	1.6	100
71	Outcome of special types of luminal breast cancer. <i>Annals of Oncology</i> , 2012, 23, 1428-1436.	1.2	99
72	Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 713-720.	2.5	98

#	ARTICLE	IF	CITATIONS
73	CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. <i>Annals of Oncology</i> , 2007, 18, 701-708.	1.2	95
74	Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. <i>Journal of Clinical Oncology</i> , 2020, 38, 1293-1303.	1.6	93
75	Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. <i>Annals of Oncology</i> , 2007, 18, 1632-1640.	1.2	92
76	Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. <i>Anti-Cancer Drugs</i> , 2006, 17, 961-967.	1.4	91
77	Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. <i>Annals of Oncology</i> , 2013, 24, 661-668.	1.2	91
78	Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1179-1188.	1.6	91
79	Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up. <i>European Journal of Surgical Oncology</i> , 2021, 47, 804-812.	1.0	91
80	Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2~ Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. <i>Clinical Cancer Research</i> , 2022, 28, 851-859.	7.0	90
81	Prediction of response to primary chemotherapy for operable breast cancer. <i>European Journal of Cancer</i> , 1999, 35, 574-579.	2.8	89
82	Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. <i>Annals of Oncology</i> , 2008, 19, 465-472.	1.2	89
83	Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. <i>Annals of Oncology</i> , 2000, 11, 1057-1060.	1.2	88
84	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 282-293.	1.6	88
85	Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 359-369.	2.5	86
86	Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. <i>Annals of Oncology</i> , 2011, 22, 2201-2207.	1.2	84
87	Guidelines on the standards for the training of specialised health professionals dealing with breast cancer. <i>European Journal of Cancer</i> , 2007, 43, 660-675.	2.8	83
88	Influence of Endocrine-Related Factors on Response to Perioperative Chemotherapy for Patients With Node-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 4141-4149.	1.6	81
89	Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and) Tj ETQq1 1 0.784314 rgBT /Over weekly paclitaxel. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 667-672.	2.3	81
90	Adjuvant Endocrine Therapy for Premenopausal Women With Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 1736-1750.	1.6	79

#	ARTICLE	IF	CITATIONS
91	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	9.4	79
92	Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ER± metastatic breast cancer. <i>Nature Genetics</i> , 2017, 49, 444-450.	21.4	77
93	Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1226-1238.	10.7	76
94	Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1898. <i>Breast Cancer Research</i> , 2019, 21, 30.	5.0	76
95	Site of Primary Tumor Has a Prognostic Role in Operable Breast Cancer: The International Breast Cancer Study Group Experience. <i>Journal of Clinical Oncology</i> , 2005, 23, 1390-1400.	1.6	74
96	Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials. <i>Breast</i> , 2013, 22, 1094-1100.	2.2	73
97	Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. <i>Annals of Oncology</i> , 2006, 17, 1497-1503.	1.2	72
98	Oncoplastic Breast-Conserving Surgery for Tumors Larger than 2 Centimeters: Is it Oncologically Safe? A Matched-Cohort Analysis. <i>Annals of Surgical Oncology</i> , 2016, 23, 1852-1859.	1.5	69
99	Research Issues Affecting Preoperative Systemic Therapy for Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 806-813.	1.6	68
100	Long-term Results of Intrapericardial Chemotherapeutic Treatment of Malignant Pericardial Effusions With Thiotepa. <i>Chest</i> , 2004, 126, 1412-1416.	0.8	67
101	Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. <i>British Journal of Cancer</i> , 2007, 97, 802-808.	6.4	67
102	Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies. <i>Annals of Oncology</i> , 2004, 15, 1633-1639.	1.2	65
103	Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 689-699.	2.5	65
104	Repeating Conservative Surgery after Ipsilateral Breast Tumor Reappearance: Criteria for Selecting the Best Candidates. <i>Annals of Surgical Oncology</i> , 2012, 19, 3771-3776.	1.5	65
105	Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor±Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. <i>Journal of Clinical Oncology</i> , 2016, 34, 3400-3408.	1.6	65
106	Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2± ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. <i>Clinical Cancer Research</i> , 2022, 28, 3433-3442.	7.0	65
107	Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution. <i>Cancer</i> , 2004, 101, 905-912.	4.1	64
108	Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 819-825.	2.5	64

#	ARTICLE	IF	CITATIONS
109	Update on the Feasibility and Progress on Robotic Breast Surgery. <i>Annals of Surgical Oncology</i> , 2019, 26, 3046-3051.	1.5	63
110	Oesophageal cancer treatment: Studies, strategies and facts. <i>Annals of Oncology</i> , 1998, 9, 951-962.	1.2	61
111	Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 277-282.	2.5	61
112	Is Adjuvant Chemotherapy Useful for Women With Luminal A Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2012, 30, 1260-1263.	1.6	60
113	Doseâ€‘response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. <i>European Journal of Cancer</i> , 1998, 34, 1693-1700.	2.8	59
114	Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. <i>British Journal of Cancer</i> , 2002, 86, 1705-1714.	6.4	59
115	Systemic Effects of Surgery: Quantitative Analysis of Circulating Basic Fibroblast Growth Factor (bFGF), Vascular Endothelial Growth Factor (VEGF) and Transforming Growth Factor Beta (TGF-Î²) in Patients with Breast Cancer Who Underwent Limited or Extended Surgery. <i>Breast Cancer Research and Treatment</i> , 2005, 93, 35-40.	2.5	59
116	Metronomic Chemotherapy Combined With Bevacizumab and Erlotinib in Patients With Metastatic HER2-Negative Breast Cancer: Clinical and Biological Activity. <i>Clinical Breast Cancer</i> , 2012, 12, 207-214.	2.4	59
117	Breast cancer subtypes and outcome after local and regional relapse. <i>Annals of Oncology</i> , 2012, 23, 324-331.	1.2	57
118	Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. <i>Annals of Oncology</i> , 2017, 28, 2225-2232.	1.2	56
119	Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptorâ€‘Positive, <i>ERBB2</i>-Negative Advanced Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 1791.	7.1	56
120	Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2-Advanced Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 419-430.	6.3	55
121	HER2 status in early breast cancer: Relevance of cell staining patterns, gene amplification and polysomy 17. <i>European Journal of Cancer</i> , 2007, 43, 2339-2344.	2.8	54
122	Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 137-144.	2.5	53
123	The clinical relevance of micropapillary carcinoma of the breast: a caseâ€‘control study. <i>Histopathology</i> , 2013, 63, 217-224.	2.9	53
124	Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptorâ€‘positive/human epidermal growth factor receptor 2â€‘negative metastatic breast cancer in PALOMA-3. <i>European Journal of Cancer</i> , 2018, 104, 21-31.	2.8	53
125	Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. <i>BMJ</i> , The, 2021, 375, e066381.	6.0	53
126	Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. <i>Annals of Oncology</i> , 2004, 15, 590-593.	1.2	52

#	ARTICLE	IF	CITATIONS
127	Immunohistochemically Defined Subtypes and Outcome of Apocrine Breast Cancer. <i>Clinical Breast Cancer</i> , 2013, 13, 95-102.	2.4	52
128	Survival Outcomes in Breast Cancer Patients With Low Estrogen/Progesterone Receptor Expression. <i>Clinical Breast Cancer</i> , 2014, 14, 258-264.	2.4	51
129	A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer. <i>European Journal of Cancer</i> , 2010, 46, 2216-2224.	2.8	50
130	Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: Are all CMFs alike?. <i>Annals of Oncology</i> , 1998, 9, 489-493.	1.2	49
131	Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 867-875.	2.5	49
132	Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": The CASA randomized trial. <i>Breast</i> , 2013, 22, 130-137.	2.2	48
133	Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Updated analyses from PALOMA-3.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1000-1000.	1.6	47
134	Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors. <i>Annals of Oncology</i> , 2007, 18, 288-292.	1.2	46
135	Results of chest wall resection for recurrent or locally advanced breast malignancies. <i>Breast</i> , 2007, 16, 297-302.	2.2	45
136	Metronomic therapy and breast cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2014, 40, 942-950.	7.7	44
137	Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. <i>British Journal of Cancer</i> , 2008, 99, 1564-1571.	6.4	43
138	Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 2015, 26, 307-313.	1.2	43
139	Lack of prognostic significance of "classic" lobular breast carcinoma: a matched, single institution series. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 211-214.	2.5	42
140	Results of a Salvage Regimen in Refractory or Relapsed Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 1994, 14, 121-128.	1.3	41
141	Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 211-218.	2.5	41
142	Phase II Study of Estramustine, Oral Etoposide, and Vinorelbine in Hormone-Refractory Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997, 20, 383-386.	1.3	41
143	Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. <i>Lancet, The</i> , 1999, 354, 130-131.	13.7	40
144	Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. <i>Annals of Oncology</i> , 2011, 22, 2216-2226.	1.2	40

#	ARTICLE	IF	CITATIONS
145	Intrapericardial Treatment of Neoplastic Pericardial Effusions. <i>Herz</i> , 2000, 25, 787-793.	1.1	39
146	Second Axillary Sentinel Lymph Node Biopsy for Breast Tumor Recurrence: Experience of the European Institute of Oncology. <i>Annals of Surgical Oncology</i> , 2015, 22, 2372-2377.	1.5	39
147	Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer. <i>Breast</i> , 2011, 20, 319-323.	2.2	38
148	Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 275-286.	2.5	37
149	Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy. <i>Cancer</i> , 2007, 110, 509-517.	4.1	36
150	A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer. <i>Annals of Oncology</i> , 2009, 20, 1178-1184.	1.2	36
151	Symptoms of endocrine treatment and outcome in the BIG 1-98 study. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 159-169.	2.5	36
152	Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1335.	7.1	36
153	Sentinel lymph node biopsy is feasible even after total mastectomy. <i>Journal of Surgical Oncology</i> , 2007, 95, 175-179.	1.7	35
154	Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting. <i>Breast</i> , 2009, 18, S137-S140.	2.2	35
155	Methylation of O 6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 131-137.	2.5	35
156	Identification and clinical validation of a multigene assay that interrogates the biology of cancer stem cells and predicts metastasis in breast cancer: A retrospective consecutive study. <i>EBioMedicine</i> , 2019, 42, 352-362.	6.1	35
157	Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. <i>Annals of Oncology</i> , 2002, 13, 895-902.	1.2	34
158	Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 259-265.	2.4	34
159	Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial. <i>Cancer Letters</i> , 2017, 400, 276-281.	7.2	34
160	Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5â€‰Years of Follow-Up. <i>Oncologist</i> , 2021, 26, e749-e755.	3.7	33
161	Topoisomerase III± gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer. <i>Breast</i> , 2008, 17, 506-511.	2.2	32
162	Timing of Radiotherapy and Outcome in Patients Receiving Adjuvant Endocrine Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 398-402.	0.8	32

#	ARTICLE	IF	CITATIONS
163	Pathological features and survival outcomes of very young patients with early breast cancer: How much is "every young"? Breast, 2013, 22, 1046-1051.	2.2	32
164	Outcome of Male Breast Cancer: A Matched Single-Institution Series. Clinical Breast Cancer, 2014, 14, 371-377.	2.4	32
165	Preoperative systemic treatment: prediction of responsiveness. Breast, 2003, 12, 538-542.	2.2	31
166	Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure. Breast Cancer Research and Treatment, 2009, 118, 385-394.	2.5	31
167	Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial. Breast Care, 2018, 13, 177-181.	1.4	31
168	Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. Breast, 2021, 59, 327-338.	2.2	31
169	Video-assisted management of malignant pleural effusion in breast carcinoma. Cancer, 2006, 106, 271-276.	4.1	29
170	A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer. Clinical Cancer Research, 2020, 26, 6149-6157.	7.0	29
171	Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. European Journal of Cancer, 1993, 29, 1658-1663.	2.8	28
172	Benefits and adverse effects of endocrine therapy. Annals of Oncology, 2010, 21, vii107-vii111.	1.2	28
173	Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer. Breast Cancer Research and Treatment, 2011, 126, 431-441.	2.5	28
174	Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy. Annals of Oncology, 2003, 14, 843-848.	1.2	27
175	Adjuvant therapies for special types of breast cancer. Breast, 2011, 20, S153-S157.	2.2	27
176	ecancermedalscience. Ecanermedalscience, 2014, 8, 463.	1.1	26
177	Pre-operative chemotherapy and radiotherapy in breast cancer. European Journal of Cancer, 1998, 34, 641-645.	2.8	26
178	Systemic treatments for women with breast cancer: outcome with relation to screening for the disease. Annals of Oncology, 2003, 14, 1212-1214.	1.2	26
179	ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of locally recurrent or metastatic breast cancer (MBC). Annals of Oncology, 2005, 16, i10-i12.	1.2	26
180	Positive axillary sentinel lymph node: Is axillary dissection always necessary?. Breast, 2011, 20, S96-S98.	2.2	26

#	ARTICLE	IF	CITATIONS
181	Outcomes of Patients With Breast Cancer Who Present With Ipsilateral Supraclavicular or Internal Mammary Lymph Node Metastases. <i>Clinical Breast Cancer</i> , 2014, 14, 53-60.	2.4	26
182	Activity of Combination Chemotherapy in Brain Metastases from Breast and Lung Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997, 20, 303-307.	1.3	26
183	Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma. <i>Anticancer Research</i> , 2004, 24, 1261-6.	1.1	26
184	Timing of adjuvant systemic therapy and radiotherapy after breast-conserving surgery and mastectomy. <i>Cancer Treatment Reviews</i> , 2010, 36, 443-450.	7.7	25
185	Oral Metronomic Cyclophosphamide and Methotrexate Plus Fulvestrant in Advanced Breast Cancer Patients: A Mono-Institutional Case-Cohort Report. <i>Breast Journal</i> , 2012, 18, 470-474.	1.0	25
186	Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab. <i>Breast</i> , 2012, 21, 309-313.	2.2	25
187	Prognostic role of CA15.3 in 7942 patients with operable breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 317-326.	2.5	25
188	Targeting bone metastatic cancer: Role of the mTOR pathway. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 248-254.	7.4	25
189	Sarcoidosis with bone involvement mimicking metastatic disease at 18F-FDG PET/CT: problem solving by diffusion whole-body MRI. <i>Ecancermedalscience</i> , 2015, 9, 537.	1.1	25
190	Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines. <i>British Journal of Cancer</i> , 2019, 121, 325-331.	6.4	25
191	Niraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study. <i>Clinical Cancer Research</i> , 2021, 27, 5482-5491.	7.0	25
192	Low-risk triple-negative breast cancers: Clinico-pathological and molecular features. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103643.	4.4	25
193	Sentinel Lymph Node Biopsy in Multicentric Breast Cancer: Five-Year Results in a Large Series from a Single Institution. <i>Annals of Surgical Oncology</i> , 2011, 18, 2879-2884.	1.5	24
194	Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies. <i>Breast Cancer Research</i> , 2020, 22, 27.	5.0	24
195	Practical Considerations in the Treatment of Hepatocellular Carcinoma. <i>Drugs</i> , 1998, 55, 367-382.	10.9	23
196	Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype. <i>Annals of Oncology</i> , 2005, 16, 1094-1099.	1.2	22
197	Unnecessary axillary node dissections in the sentinel lymph node era. <i>European Journal of Cancer</i> , 2007, 43, 2664-2668.	2.8	22
198	Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. <i>Annals of Oncology</i> , 2010, 21, 245-254.	1.2	22

#	ARTICLE	IF	CITATIONS
199	Neoadjuvant chemotherapy for breast cancer: any progress?. <i>Lancet Oncology</i> , The, 2014, 15, 131-132.	10.7	22
200	Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast Cancer Study Group Trials VI and VII. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 273-279.	0.8	22
201	Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. <i>Breast Cancer Research</i> , 2016, 18, 110.	5.0	22
202	Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy. <i>Breast</i> , 2017, 34, 83-88.	2.2	22
203	Chemotherapy (CT) de-escalation using an FDG-PET/CT (F-PET) and pathological response-adapted strategy in HER2[+] early breast cancer (EBC): PHERGain Trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 503-503.	1.6	22
204	Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer. <i>British Journal of Cancer</i> , 2008, 98, 1745-1752.	6.4	21
205	Ductal Intraepithelial Neoplasia: Postsurgical Outcome for 1,267 Women Cared for in One Single Institution over 10 Years. <i>Oncologist</i> , 2009, 14, 201-212.	3.7	21
206	Bone Quality Test (BQT) scores of fingernails in postmenopausal patients treated with adjuvant letrozole or tamoxifen for early breast cancer. <i>Breast</i> , 2009, 18, 84-88.	2.2	21
207	Breast-conserving surgery in 201 very young patients (<35 years). <i>Breast</i> , 2010, 19, 55-58.	2.2	21
208	Lobular Metastatic Breast Cancer Patients With Gastrointestinal Involvement: Features and Outcomes. <i>Clinical Breast Cancer</i> , 2018, 18, e401-e405.	2.4	21
209	Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 23-35.	2.5	21
210	Primary chemotherapy in operable breast cancer with favorable prognostic factors: A pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN). <i>Annals of Oncology</i> , 1999, 10, 993-996.	1.2	20
211	Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 965-971.	2.3	20
212	Phase II Trial of Combination of Pegylated Liposomal Doxorubicin, Cisplatin, and Infusional 5-Fluorouracil (CCF) Plus Trastuzumab as Preoperative Treatment for Locally Advanced and Inflammatory Breast Cancer. <i>Clinical Breast Cancer</i> , 2010, 10, 483-488.	2.4	20
213	Letrozole. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 251-259.	3.3	20
214	Classic Kaposi's Sarcoma: A Review of 90 Cases. <i>Journal of Dermatology</i> , 1992, 19, 548-552.	1.2	19
215	Medical Treatment of Hepatocellular Carcinoma: Any Progress?. <i>Tumori</i> , 1994, 80, 315-326.	1.1	19
216	Goserelin in Premenopausal Advanced Breast Cancer: Clinical and Endocrine Evaluation of Responsive Patients. <i>Oncology</i> , 1994, 51, 262-269.	1.9	19

#	ARTICLE	IF	CITATIONS
217	Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. <i>British Journal of Cancer</i> , 2008, 98, 25-33.	6.4	19
218	Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 455-459.	2.5	19
219	Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 347-359.	2.5	19
220	Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2 ⁺ advanced breast cancer (ABC) treated with endocrine therapy \pm ribociclib: Overall survival (OS) results.. <i>Journal of Clinical Oncology</i> , 2019, 37, LBA1008-LBA1008.	1.6	19
221	Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. <i>Annals of Oncology</i> , 2005, 16, 716-725.	1.2	18
222	Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features. <i>Anti-Cancer Drugs</i> , 2009, 20, 197-203.	1.4	18
223	PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy. <i>Npj Breast Cancer</i> , 2021, 7, 47.	5.2	18
224	ecancermedalscience. <i>Ecancermedalscience</i> , 2013, 7, 299.	1.1	17
225	Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: A phase II study. <i>Annals of Oncology</i> , 2001, 12, 95-100.	1.2	17
226	Management of advanced breast cancer. <i>Annals of Oncology</i> , 2007, 18, vi74-vi76.	1.2	17
227	Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591989410.	3.2	17
228	Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 1.	5.2	17
229	New Criteria for Selecting Elderly Patients for Breast Cancer Adjuvant Treatment Studies. <i>Oncologist</i> , 2007, 12, 952-959.	3.7	16
230	Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 386-395.	1.6	16
231	Adjuvant Therapy for Very Young Women with Breast Cancer: Response According to Biologic and Endocrine Features. <i>Clinical Breast Cancer</i> , 2004, 5, 125-130.	2.4	15
232	Factor V Leiden Mutation in Patients with Breast Cancer with a Central Venous Catheter: Risk of Deep Vein Thrombosis. <i>Supportive Cancer Therapy</i> , 2006, 3, 98-102.	0.3	15
233	The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. <i>Annals of Oncology</i> , 2009, 20, 1344-1351.	1.2	15
234	Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1834-1841.	6.4	15

#	ARTICLE	IF	CITATIONS
235	Influence of Margin Status on Outcomes in Lobular Carcinoma. <i>Annals of Surgery</i> , 2011, 253, 580-584.	4.2	15
236	HER2-negative (1+) breast cancer with unfavorable prognostic features: to FISH or not to FISH?. <i>Annals of Oncology</i> , 2012, 23, 1371-1372.	1.2	15
237	Time to Initiation of Adjuvant Chemotherapy for Early Breast Cancer and Outcome: The Earlier, the Better?. <i>Journal of Clinical Oncology</i> , 2014, 32, 717-719.	1.6	15
238	Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib. <i>JCO Precision Oncology</i> , 2021, 5, 1408-1420.	3.0	15
239	Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) HER2-negative breast cancer (BC): Results from TEXT and SOFT.. <i>Journal of Clinical Oncology</i> , 2018, 36, 503-503.	1.6	15
240	Prediction of cancer outcome with microarrays. <i>Lancet, The</i> , 2005, 365, 1683.	13.7	14
241	Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancer. <i>Breast</i> , 2007, 16, 73-80.	2.2	14
242	Metronomics in the neoadjuvant and adjuvant treatment of breast cancer. <i>Cancer Letters</i> , 2017, 400, 259-266.	7.2	14
243	Oncoplastic breast surgery for the management of ductal carcinoma in situ (DCIS): is it oncologically safe? A retrospective cohort analysis. <i>European Journal of Surgical Oncology</i> , 2018, 44, 957-962.	1.0	14
244	Local therapy for breast cancer in malignant lymphoma survivors. <i>Breast</i> , 2011, 20, S99-S103.	2.2	13
245	Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 328-335.	2.4	13
246	Estimation of historical control rate for a single arm de-escalation study - Application to the POSITIVE trial. <i>Breast</i> , 2020, 53, 1-7.	2.2	13
247	Megestrol Acetate in Unresectable Hepatocellular Carcinoma. <i>Tumori</i> , 1995, 81, 351-353.	1.1	12
248	Radiotherapy and Chemotherapy in High-Risk Breast Cancer. <i>New England Journal of Medicine</i> , 1998, 338, 329-333.	27.0	12
249	Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): Is prophylaxis required?. <i>Annals of Oncology</i> , 2000, 11, 117-118.	1.2	12
250	Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter. <i>Supportive Care in Cancer</i> , 2007, 15, 1213-1217.	2.2	12
251	Optimal management of luminal breast cancer: how much endocrine therapy is long enough?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877743.	3.2	12
252	Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab. <i>Targeted Oncology</i> , 2019, 14, 647-656.	3.6	12

#	ARTICLE	IF	CITATIONS
253	A Dose-Escalating Study of Carboplatin Combined with Vinorelbine in Non-Small-Cell Lung Cancer. <i>Oncology</i> , 1996, 53, 364-368.	1.9	11
254	Combined chemo-endocrine adjuvant therapy for patients with operable breast cancer: Still a question?. <i>Cancer Treatment Reviews</i> , 1998, 24, 15-26.	7.7	11
255	Bone scan had no role in the staging of 765 consecutive operable T1â€“2N0â€“1 breast cancer patients without skeletal symptoms. <i>Annals of Oncology</i> , 2001, 12, 724-725.	1.2	11
256	A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer. <i>Anti-Cancer Drugs</i> , 2006, 17, 1201-1209.	1.4	11
257	Neoadjuvant therapy in locally advanced breast cancer: 99mTc-MIBI mammoscintigraphy is not a reliable technique to predict therapy response. <i>Breast</i> , 2007, 16, 262-270.	2.2	11
258	Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group. <i>Supportive Care in Cancer</i> , 2008, 16, 67-74.	2.2	11
259	Multicentric breast cancer with heterogeneous histopathology: a multidisciplinary review. <i>Future Oncology</i> , 2020, 16, 395-412.	2.4	11
260	Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study. <i>Drug Safety</i> , 2020, 43, 233-242.	3.2	11
261	Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations. <i>Breast</i> , 2021, 59, 94-101.	2.2	11
262	The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: Ready for prime time?. <i>Cancer Treatment Reviews</i> , 2013, 39, 886-890.	7.7	10
263	Prevalence and Clinicopathologic Correlates of O6-Methylguanine-DNA Methyltransferase Methylation Status in Patients With Triple-Negative Breast Cancer Treated Preoperatively by Alkylating Drugs. <i>Clinical Breast Cancer</i> , 2014, 14, 285-290.	2.4	10
264	Oral chemotherapy in advanced breast cancer: expert perspectives on its role in clinical practice. <i>Cancer Treatment Communications</i> , 2016, 6, S1-S10.	0.4	10
265	Reply to L. Moscetti. <i>Journal of Clinical Oncology</i> , 2017, 35, 1628-1628.	1.6	10
266	Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIIIâ€“IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 557-568.	2.5	10
267	Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence. <i>Breast Cancer Research</i> , 2019, 21, 153.	5.0	10
268	Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase. <i>Annals of Oncology</i> , 2003, 14, 1477-1483.	1.2	9
269	Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 573-582.	2.5	9
270	Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy. <i>Breast</i> , 2020, 53, 138-142.	2.2	9

#	ARTICLE	IF	CITATIONS
271	Preservation of quality of life in patients with human epidermal growth factor receptor 2 ⁺ positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB ³ trial). <i>European Journal of Cancer</i> , 2021, 153, 223-233.	2.8	9
272	Primary Cutaneous Rhabdomyosarcoma in Adults-Description of an Uncommon Aggressive Disease. <i>Acta Oncol³gica</i> , 1996, 35, 494-495.	1.8	8
273	Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. <i>Annals of Oncology</i> , 2007, 18, 1177-1184.	1.2	8
274	Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors. <i>Breast</i> , 2008, 17, 654-660.	2.2	8
275	Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer. <i>Breast</i> , 2011, 20, 34-38.	2.2	8
276	Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. <i>Annals of Oncology</i> , 2015, 26, 2442-2449.	1.2	8
277	Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 697-707.	2.5	8
278	Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. <i>European Journal of Cancer</i> , 2022, 164, 39-51.	2.8	8
279	Role of Endocrine Responsiveness and HER2/neu Overexpression in Inflammatory Breast Cancer Treated with Multimodality Preoperative Therapy. <i>Breast Journal</i> , 2008, 14, 435-441.	1.0	7
280	Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report. <i>Annals of Oncology</i> , 2010, 21, 667-668.	1.2	7
281	Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer. <i>European Journal of Cancer</i> , 1995, 31, 2426-2427.	2.8	6
282	Intra-arterial chemotherapy followed by chemo-embolisation in unresectable hepatocellular carcinoma. <i>European Journal of Cancer</i> , 1997, 33, 56-60.	2.8	6
283	Reply to the article "Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity" by V. R. Rozados et al. (<i>Ann Oncol</i> 2004; 15: 1543-1550): "and in humans?". <i>Annals of Oncology</i> , 2005, 16, 673.	1.2	6
284	Preoperative therapy with trastuzumab and oral vinorelbine (± endocrine therapy) in patients with HER2-positive breast cancer. <i>Breast</i> , 2010, 19, 128-132.	2.2	6
285	Receptor status (ER, PgR and HER2) discordance between primary tumor and locoregional recurrence in breast cancer. <i>Annals of Oncology</i> , 2011, 22, 479-480.	1.2	6
286	Picking the optimal endocrine adjuvant treatment for pre-menopausal women. <i>Breast</i> , 2015, 24, S11-S14.	2.2	6
287	EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 83.	5.0	6
288	Fluorouracil plus Folinic Acid in Metastatic Adenocarcinoma of Unknown Primary Site Suggestive of a Gastrointestinal Primary. <i>Tumori</i> , 1993, 79, 116-118.	1.1	5

#	ARTICLE	IF	CITATIONS
289	Evaluation of Ki-67 expression as a prognostic feature in hepatocellular carcinoma in cirrhosis. <i>European Journal of Cancer</i> , 1995, 31, 1547-1548.	2.8	5
290	Phase II Study of Oral L-Leucovorin, 120-Hour Fluorouracil Infusion and Carboplatin in Advanced Pancreatic Cancer. <i>Tumori</i> , 1996, 82, 573-575.	1.1	5
291	Treatment of advanced breast cancer: the good, the bad and the ugly. <i>Annals of Oncology</i> , 2005, 16, 1219-1221.	1.2	5
292	Focusing on physical function limitations in elderly women surviving cancer: any opportunity for improvement?. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 598-599.	4.3	5
293	Role of fluorodeoxyglucose positron emission tomography in the staging of patients with breast cancer candidated to surgery. <i>Annals of Oncology</i> , 2007, 18, 394-395.	1.2	5
294	A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer. <i>Breast</i> , 2012, 21, 621-628.	2.2	5
295	PET/CT and breast cancer subtypes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1301-1303.	6.4	5
296	Tailoring Adjuvant Treatments for the Individual Patient with Luminal Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 703-714.	2.2	5
297	Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer. <i>Drugs</i> , 2015, 75, 1311-1321.	10.9	5
298	Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 351-360.	2.5	5
299	Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. <i>British Journal of Cancer</i> , 2019, 120, 959-967.	6.4	5
300	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-Positive Early Breast Cancer: Results from the SOLE Trial. <i>Clinical Cancer Research</i> , 2021, 27, 504-512.	7.0	5
301	Low-dose oral cyclophosphamide-methotrexate maintenance (CMM) for receptor-negative early breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 1002-1002.	1.6	5
302	In-depth gene expression analysis of premenopausal patients with HR+/HER2 ⁺ advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1018-1018.	1.6	5
303	Adjuvant Chemotherapy for Cancer of Gastrointestinal Tract: A Critical Review. <i>Tumori</i> , 1992, 78, 228-234.	1.1	4
304	Mitoxantrone, Fluorouracil plus L-Leucovorin, and Vinorelbine in Pretreated Advanced Breast Cancer. <i>Oncology</i> , 1995, 52, 435-438.	1.9	4
305	Hepatic toxicity from cyclophosphamide, methotrexate, fluorouracil (CMF regimen). <i>Annals of Oncology</i> , 1999, 10, 1394-1395.	1.2	4
306	Pharmacokinetics of Oral Doxifluridine in Patients with Colorectal Cancer. <i>Tumori</i> , 1999, 85, 47-50.	1.1	4

#	ARTICLE	IF	CITATIONS
307	Prediction of cancer outcome with microarrays. <i>Lancet, The</i> , 2005, 365, 1685-1686.	13.7	4
308	Extended adjuvant chemotherapy in endocrine non-responsive disease. <i>Breast</i> , 2013, 22, S161-S164.	2.2	4
309	Whole-body magnetic resonance imaging, metastatic breast cancer and pregnancy: A case report. <i>Breast</i> , 2014, 23, 295-296.	2.2	4
310	The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients. <i>Anti-Cancer Drugs</i> , 2022, 33, e628-e634.	1.4	4
311	Predictors of positive axillary non-sentinel lymph nodes in breast cancer patients with positive sentinel lymph node biopsy after neoadjuvant systemic therapy. <i>Radiotherapy and Oncology</i> , 2021, 163, 128-135.	0.6	4
312	Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 529-529.	1.6	4
313	Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2 ^{â€}) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b ComPLEEment-1 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1056-1056.	1.6	4
314	Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 527-527.	1.6	4
315	Subcutaneous Low-Dose Interleukin-2 plus Alpha Interferon in Advanced Malignant Melanoma. <i>Tumori</i> , 1993, 79, 187-190.	1.1	3
316	Evidence of responsiveness to chemotherapy in aggressive Rosai-Dorfman disease. <i>European Journal of Cancer</i> , 1995, 31, 424.	2.8	3
317	Can tamoxifen relieve motion sickness?. <i>Annals of Oncology</i> , 2005, 16, 1713-1714.	1.2	3
318	Prophylaxis for Venous Thromboembolism in Cancer Patients With a Central Vein Catheter: New Tones for an Old Song. <i>Journal of Clinical Oncology</i> , 2005, 23, 7243-7244.	1.6	3
319	Primary systemic therapy on local advance breast cancer, where are we going?. <i>Annals of Oncology</i> , 2006, 17, vii18-vii21.	1.2	3
320	Nonrandomized Comparison between Concomitant and Sequential Chemoradiotherapy with Anthracyclines in Breast Cancer. <i>Tumori</i> , 2015, 101, 64-71.	1.1	3
321	Breast Adjuvant Radiotherapy Amid the COVID-19 Crisis in a Hub Cancer Center, Lombardy, Italy. <i>Breast Care</i> , 2021, 16, 500-506.	1.4	3
322	Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 557-557.	1.6	3
323	Pegylated Liposomal Doxorubicin (Caelyx ^Â) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial. <i>Current Oncology</i> , 2021, 28, 5167-5178.	2.2	3
324	A Randomized Phase II Trial of Two Different Schedules of Mitomycin C and Vinorelbine in Pretreated Breast Cancer. <i>Oncology</i> , 1997, 54, 438-439.	1.9	2

#	ARTICLE	IF	CITATIONS
325	Activity and Tolerability of Courses of Intra-Arterial Chemotherapy Followed by Chemoembolization in Unresectable Hepatocellular Carcinoma. Tumori, 1998, 84, 673-676.	1.1	2
326	Lesson learned from high-dose chemotherapy for high-risk breast cancer (What you see is what you) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.2	2
327	Intermittent Letrozole Administration as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptorâ€“Positive Early Breast Cancer: A Biologic Study. Clinical Breast Cancer, 2015, 15, e257-e262.	2.4	2
328	Clinical behavior of recurrent hormone receptorâ€“positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1â€“98 clinical trial. Cancer, 2021, 127, 700-708.	4.1	2
329	Metronomic Chemotherapy in Breast Cancers. , 2014, , 93-110.		2
330	Predictors of prolonged benefit from palbociclib (PAL) plus fulvestrant (F) in women with endocrine-resistant hormone receptorâ€“positive/human epidermal growth factor receptor 2â€“negative (HR+/HER2â€“) advanced breast cancer (ABC) in PALOMA-3.. Journal of Clinical Oncology, 2017, 35, 1050-1050.	1.6	2
331	Hematologic adverse events following palbociclib (PAL) dose reduction in patients (pts) with hormone receptorâ€“positive (HR+)/human epidermal growth factor receptor 2â€“negative (HER2â€“) advanced breast cancer (ABC): Pooled analysis from randomized phase 2 and 3 studies.. Journal of Clinical Oncology, 2018, 36, 1060-1060.	1.6	2
332	Well-Differentiated Neuroendocrine Carcinoma of the Lung: A Case Report. Tumori, 1991, 77, 282-284.	1.1	1
333	Reversal of Resistance to Doxifluridine and Fluorouracil in Metastatic Colorectal Cancer: The Role of High-Dose Folinic Acid. Tumori, 1992, 78, 258-261.	1.1	1
334	Clinical Development of new Fluoropyrimidines: A Major Improvement in Colorectal Cancer Treatment?. Tumori, 1995, 81, 303-307.	1.1	1
335	Reply to the Letter to the Editor on â€“Costâ€“opportunity analysis in clinical oncology: from the â€œwild far-westâ€“to a correct integration of the disciplines, avoiding the â€œwar of the worldsâ€“â„Ž, by D. Tassinari et al. (Ann Oncol 2006; 17: 877). Annals of Oncology, 2006, 17, 878.	1.2	1
336	Metronomic Chemotherapy in Elderly Patients: Do Risks Exceed Benefits in Some Patients?. Tumori, 2009, 95, 130-130.	1.1	1
337	The role of maintenance strategies in breast cancer. Memo - Magazine of European Medical Oncology, 2014, 7, 152-156.	0.5	1
338	Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive disease. Ecancermedicalscience, 2015, 9, 544.	1.1	1
339	Outcome and Medial Presentation of Breast Cancer: European Institute of Oncology Experience. Clinical Breast Cancer, 2015, 15, 440-447.	2.4	1
340	Neoadjuvant nab-paclitaxel in breast cancer: trial results and patient care. Lancet Oncology, The, 2016, 17, 265-266.	10.7	1
341	ER and immune-related signatures define benefit to palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ breast cancer patients in the NA-PHER2 trial.. Journal of Clinical Oncology, 2021, 39, 555-555.	1.6	1
342	The prognostic performance of PREDICT+ in patients (pts) with HER2-positive (HER2+) early-stage breast cancer (EBC).. Journal of Clinical Oncology, 2021, 39, 524-524.	1.6	1

#	ARTICLE	IF	CITATIONS
343	Adjuvant treatment for triple negative breast cancer with residual tumor after neo-adjuvant chemotherapy. A single institutional retrospective analysis. <i>Breast</i> , 2021, 59, 351-357.	2.2	1
344	Treatment effect of palbociclib (PAL) plus endocrine therapy (ET) by prognostic and intrinsic subtype: A joint analysis of PALOMA2 and PALOMA3.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1023-1023.	1.6	1
345	Molecular alterations and late recurrence in postmenopausal women with hormone receptor-positive node-positive breast cancer (BC): Results from the "SOLE" trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 517-517.	1.6	1
346	Efficacy analyses of central laboratory pCR results from the LILAC study comparing the biosimilar ABP 980 and trastuzumab.. <i>Journal of Clinical Oncology</i> , 2018, 36, 583-583.	1.6	1
347	Cardiac safety of the trastuzumab biosimilar ABP 980 in women with HER2-positive early breast cancer in the LILAC study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 557-557.	1.6	1
348	Feasibility of paclitaxel in a patient with anthracycline-induced congestive heart failure. <i>European Journal of Cancer</i> , 1997, 33, 321-322.	2.8	0
349	Assessment of response in primary chemotherapy for breast cancer. <i>Annals of Oncology</i> , 1998, 9, 1140-1141.	1.2	0
350	Introducing taxanes in the adjuvant treatment of breast cancer: expectations and reality. <i>Breast</i> , 2000, 9, 134-138.	2.2	0
351	Perioperative Chemotherapy in Patients With Node-Negative Postmenopausal Breast Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 2210-2212.	1.6	0
352	New technologies for diagnosis and treatment of breast cancer: meeting highlights from the Third Milan Breast Cancer Conference (Milan, June 13-15, 2001). <i>Breast</i> , 2002, 11, 185.	2.2	0
353	Special issues of systemic treatments. <i>Breast</i> , 2002, 11, 200-201.	2.2	0
354	Adjuvant systemic therapies for patients with breast cancer: Endocrine responsiveness and effects of chemotherapy. <i>Current Problems in Cancer</i> , 2003, 27, 13-16.	2.0	0
355	Adjuvant Chemotherapy in Breast Cancer: Back to the Future. <i>Oncology Research and Treatment</i> , 2003, 26, 111-112.	1.2	0
356	Adjuvant Therapy in Elderly Patients with Early Breast Cancer. <i>Current Cancer Therapy Reviews</i> , 2006, 2, 315-325.	0.3	0
357	Daily low-dose aspirin in cancer patients with central venous catheter: new role for an old drug. <i>Supportive Care in Cancer</i> , 2008, 16, 313-314.	2.2	0
358	Adjuvant Systemic Therapies by Subtypes: Guidelines. , 2017, , 535-539.		0
359	Systematic review and meta-analysis of post-progression outcomes in ER+/HER2- metastatic breast cancer after treatment with endocrine therapy and CDK 4/6 inhibitors within randomized clinical trials.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1059-1059.	1.6	0
360	Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 137-145.	2.5	0

#	ARTICLE	IF	CITATIONS
361	Intrinsic subtype and its clinical significance in early node-negative breast cancer: Results from two randomized trials of adjuvant chemoendocrine therapy.. Journal of Clinical Oncology, 2012, 30, 504-504.	1.6	0
362	Management of breast cancer during pregnancy: Results of a large registry from a single institution.. Journal of Clinical Oncology, 2013, 31, 589-589.	1.6	0
363	Estimation of historical control rate for a single arm de-escalation study: Application to the POSITIVE trial.. Journal of Clinical Oncology, 2018, 36, 552-552.	1.6	0
364	Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy: A Breast International Group (BIG) 1-98 sub-analyses.. Journal of Clinical Oncology, 2019, 37, 538-538.	1.6	0
365	Comparison of StemPrintER, a novel biology-based genomic predictor of distant recurrence in breast cancer, with Oncotype DX in the TransATAC cohort.. Journal of Clinical Oncology, 2020, 38, 1020-1020.	1.6	0
366	Biological and clinical features of early triple-negative invasive lobular carcinomas of the breast.. Journal of Clinical Oncology, 2020, 38, e12570-e12570.	1.6	0
367	Integration of the stem cell biology-based genomic tool, StemPrintER, with clinicopathological parameters for the prediction of distant recurrence in ER+/HER2- breast cancer (BC) patients.. Journal of Clinical Oncology, 2020, 38, 1057-1057.	1.6	0
368	Abstract GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial. Cancer Research, 2022, 82, GS1-07-GS1-07.	0.9	0
369	Abstract OT1-12-07: A phase 2 study of chemotherapy de-escalation using a pathological response-guided strategy in patients with HER2-positive, low-risk early breast cancer: PHERGain-2. Cancer Research, 2022, 82, OT1-12-07-OT1-12-07.	0.9	0
370	Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy. European Journal of Cancer, 2022, 164, 52-61.	2.8	0